Regeneron announced positive 84-week results from its Phase 3 OPTIMA trial for Pasatru in treating Fibrodysplasia Ossificans Progressiva (FOP), demonstrating sustained efficacy in preventing new bone growth and reducing flare-ups. This reinforces the drug's market position following its recent FDA approval, suggesting continued strong performance in this rare disease indication.
Regeneron announced positive 84-week data from its Phase 3 OPTIMA trial for Pasatru, a drug for Fibrodysplasia Ossificans Progressiva (FOP). The data showed sustained efficacy in halting new bone growth and reducing disease flare-ups, building on the 56-week data that led to its recent FDA approval. This is significant because it validates the long-term effectiveness of Pasatru, strengthening its market position in a rare and debilitating disease. For traders, this reinforces the positive outlook for REGN, as it confirms the drug's value and potential for sustained revenue generation, reducing long-term clinical risk for this product.